Different induction therapy protocols experience based on depleting antibodies for kidney transplantation

Aim. To analyze the efficacy and safety of different induction therapy protocols experience based on depleting antibodies for kidney transplantation (ATGAM, Timoglobulin).Material and methods. The study included 107 non-sensitized patients who underwent primary kidney allotransplantation in the peri...

Full description

Bibliographic Details
Main Authors: S. V. Arzumanov, D. V. Tiptsov, A. E. Mitish, A. K. Gramotnev
Format: Article
Language:English
Published: N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department 2016-02-01
Series:Трансплантология (Москва)
Subjects:
Online Access:https://www.jtransplantologiya.ru/jour/article/view/42
_version_ 1797759275016126464
author S. V. Arzumanov
D. V. Tiptsov
A. E. Mitish
A. K. Gramotnev
author_facet S. V. Arzumanov
D. V. Tiptsov
A. E. Mitish
A. K. Gramotnev
author_sort S. V. Arzumanov
collection DOAJ
description Aim. To analyze the efficacy and safety of different induction therapy protocols experience based on depleting antibodies for kidney transplantation (ATGAM, Timoglobulin).Material and methods. The study included 107 non-sensitized patients who underwent primary kidney allotransplantation in the period from January 2012 to March 2014. Patients were divided into 3 groups according to the ongoing induction immunosuppressive therapy. Group I, patients receiving the drug ATGAM (n = 67). Group II – Timoglobulin (n = 30). Group III, patients received a combination of the introduction of basiliximab and ATGAM (n = 10). All patients received basic triple immunosuppressive therapy: tacrolimus, mycophenolic acid, methylprednisolone tapering.Results. The incidence of acute rejection in group I – 7,5% , in group II – 0%, in group III – 0% (p = 0,15). The incidence of severe thrombocytopenia in group I – 2,7%, in group II – 0% (p < 0,05), in group III – 10%. Incidence of CMV viremia in group I – 6,16%, in group II – 6,6%, in the group III – 10%, respectively (p > 0,05). In the 2-nd and 3-rd group registered one case of CMV pneumonia in the early postoperative period.Conclusion. Use of exhaustible polyclonal antibodies as drugs of choice for renal transplantation induction therapy in primary unsensitized patients is warranted. Further research is needed for evaluation of 5- and 10-year results.
first_indexed 2024-03-12T18:42:04Z
format Article
id doaj.art-b0c4ea4daf9243ebb94069c751e81918
institution Directory Open Access Journal
issn 2074-0506
2542-0909
language English
last_indexed 2024-03-12T18:42:04Z
publishDate 2016-02-01
publisher N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department
record_format Article
series Трансплантология (Москва)
spelling doaj.art-b0c4ea4daf9243ebb94069c751e819182023-08-02T07:48:49ZengN.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare DepartmentТрансплантология (Москва)2074-05062542-09092016-02-0102141942Different induction therapy protocols experience based on depleting antibodies for kidney transplantationS. V. Arzumanov0D. V. Tiptsov1A. E. Mitish2A. K. Gramotnev3НИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ГБУ «Национальный медицинский радиологический центр» МЗ РФНИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ГБУ «Национальный медицинский радиологический центр» МЗ РФНИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ГБУ «Национальный медицинский радиологический центр» МЗ РФНИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ГБУ «Национальный медицинский радиологический центр» МЗ РФAim. To analyze the efficacy and safety of different induction therapy protocols experience based on depleting antibodies for kidney transplantation (ATGAM, Timoglobulin).Material and methods. The study included 107 non-sensitized patients who underwent primary kidney allotransplantation in the period from January 2012 to March 2014. Patients were divided into 3 groups according to the ongoing induction immunosuppressive therapy. Group I, patients receiving the drug ATGAM (n = 67). Group II – Timoglobulin (n = 30). Group III, patients received a combination of the introduction of basiliximab and ATGAM (n = 10). All patients received basic triple immunosuppressive therapy: tacrolimus, mycophenolic acid, methylprednisolone tapering.Results. The incidence of acute rejection in group I – 7,5% , in group II – 0%, in group III – 0% (p = 0,15). The incidence of severe thrombocytopenia in group I – 2,7%, in group II – 0% (p < 0,05), in group III – 10%. Incidence of CMV viremia in group I – 6,16%, in group II – 6,6%, in the group III – 10%, respectively (p > 0,05). In the 2-nd and 3-rd group registered one case of CMV pneumonia in the early postoperative period.Conclusion. Use of exhaustible polyclonal antibodies as drugs of choice for renal transplantation induction therapy in primary unsensitized patients is warranted. Further research is needed for evaluation of 5- and 10-year results.https://www.jtransplantologiya.ru/jour/article/view/42лимфоцитоистощающие антителаострое отторжениеиндукционная терапияцитомегаловирус
spellingShingle S. V. Arzumanov
D. V. Tiptsov
A. E. Mitish
A. K. Gramotnev
Different induction therapy protocols experience based on depleting antibodies for kidney transplantation
Трансплантология (Москва)
лимфоцитоистощающие антитела
острое отторжение
индукционная терапия
цитомегаловирус
title Different induction therapy protocols experience based on depleting antibodies for kidney transplantation
title_full Different induction therapy protocols experience based on depleting antibodies for kidney transplantation
title_fullStr Different induction therapy protocols experience based on depleting antibodies for kidney transplantation
title_full_unstemmed Different induction therapy protocols experience based on depleting antibodies for kidney transplantation
title_short Different induction therapy protocols experience based on depleting antibodies for kidney transplantation
title_sort different induction therapy protocols experience based on depleting antibodies for kidney transplantation
topic лимфоцитоистощающие антитела
острое отторжение
индукционная терапия
цитомегаловирус
url https://www.jtransplantologiya.ru/jour/article/view/42
work_keys_str_mv AT svarzumanov differentinductiontherapyprotocolsexperiencebasedondepletingantibodiesforkidneytransplantation
AT dvtiptsov differentinductiontherapyprotocolsexperiencebasedondepletingantibodiesforkidneytransplantation
AT aemitish differentinductiontherapyprotocolsexperiencebasedondepletingantibodiesforkidneytransplantation
AT akgramotnev differentinductiontherapyprotocolsexperiencebasedondepletingantibodiesforkidneytransplantation